Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00619619 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder
A Phase 2 study of Depression and Major Depressive Disorder, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 9
- Study locations
NCT00619619: Completed Phase 2 study of Depression and Major Depressive Disorder, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00619619 is a Phase 2 study of Depression and Major Depressive Disorder that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 59 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (92% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00619619, a Phase 2 study of Depression and Major Depressive Disorder, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 9
- Study locations
Study Summary
The primary purpose of this study is to test the safety and tolerability of single ascending doses of Desvenlafaxine Succinate Sustained-Release (DVS SR) in both child and adolescent outpatients with major depressive disorder. This study will also characterize the pharmacokinetic profile of DVS SR in children and adolescents with major depressive disorder.
Primary Outcome
AEs are any untoward, undesired, or unplanned event in the form of signs, symptoms, disease, or laboratory or physiologic observations occurring in a person given study treatment. The event does not need to be causally related to the study treatment. SAEs are adverse events that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in persistent or significant disability or incapacity, result in cancer, or result in a congenital anomaly or birt
Conditions Studied
Interventions
- DRUG Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Study Locations (9)
Arkansas
- Pfizer Investigational Site - Little Rock
Florida
- Pfizer Investigational Site - North Miami
Indiana
- Pfizer Investigational Site - Terre Haute
Kansas
- Pfizer Investigational Site - Wichita
Louisiana
- Pfizer Investigational Site - New Orleans
New York
- Pfizer Investigational Site - New York
Ohio
- Pfizer Investigational Site - Cleveland
Pennsylvania
- Pfizer Investigational Site - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
What the finished NCT00619619 record still lists
NCT00619619 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) is the first listed.
NCT00619619 lists 9 locations in 9 states (Arkansas, Florida, Indiana).
Frequently Asked Questions
What is clinical trial NCT00619619 about?
NCT00619619 is a clinical study titled "Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder". The primary purpose of this study is to test the safety and tolerability of single ascending doses of Desvenlafaxine Succinate Sustained-Release (DVS SR) in both child and adolescent outpatients with major depressive disorder. This study will also characterize the pharmacokinetic profile of DVS SR i...
What is the current status of trial NCT00619619?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2008-02. Estimated completion is 2009-11.
What conditions does trial NCT00619619 study?
This clinical trial studies the following conditions: Depression, Major Depressive Disorder.
What interventions are being tested in trial NCT00619619?
The interventions under investigation include: Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) (DRUG).
Who is sponsoring clinical trial NCT00619619?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00619619 being conducted?
This trial has 9 study locations across Arkansas, Florida, Indiana, Kansas, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00619619's enrollment target sits among peer trials
59 447th of 679 higher than 232 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia